Abstract:
화학식 1로 나타내어지는 2-사이클로펜텐-1-온 옥심유도체를 포함하는 비만, 이상지질혈증, 당뇨 등과 같은 지방대사질환 예방 및 치료용 약학조성물이 개시된다. 구체적으로 상기 화합물은 분화된 지방세포 (3T3-L1)에서의 지방분해를 촉진시켜 결과적으로 체내 지방을 감소시킴으로써, 비만, 이상지질혈증, 당뇨 등과 같은 지방대사 질환의 예방 및 치료에 이용될 수 있다. 화학식 1에서 R 1 은 선형 또는 분지형 C 1 -C 6 알킬기, 또는 사이클로알킬기, 또는 치환기를 갖거나 갖지 않는 페닐기를 의미하고, R 2 는 치환기를 가지거나 가지지 않는 방향족기를 의미한다.
Abstract:
본 고안은 요일별로 램프의 발광시간 및 횟수를 세팅시킨후 요일마다 별도로 점등되어 사용해야할 화장품을 알려주고 아울러 세팅된 시간 및 횟수가 끝나면 소등되도록 한 것을 특징으로 하는 엘이디 알람 기능을 갖는 가정용 화장품 진열대에 관한 것으로, 한개 이상의 삽입홈이 형성된 화장품 진열용 케이스와; 상기 삽입홈에 형성되는 조명수단과; 상기 삽입홈의 내측하단에 설치되는 무게 감지수단과; 상기 화장품 진열용 케이스의 측면에 형성되며, 화장품의 요일선택 및 사용 횟수 선택을 위한 정보 입력수단과; 상기 입력수단과, 무게감지수단과, 조명수단에 전기적으로 연결되며, 입력수단으로부터 요일별 및 횟수별 정보를 입력받아 메모리하고, 무게감지수단으로부터 화장품의 존재유무를 파악함과 동시에 화장품이 삽입홈로부터 인출되는 횟수를 파악하며, 입력수단으로부터 입력된 요일이 되면 해당 번호의 조명수단를 점등시키고 사용자가 삽입홈로부터 화장품을 인출하면 조명수단를 소등하며, 삽입홈으로 입력하면 다시 해당 번호를 점등하되 해당횟수만큼 화장품의 사용이 마무리되면 엘이디를 소등시키도록 제어하는 제어수단 및; 상기 조명수단에 전원을 공급하기 위한 전원공급수단을 포함하여 구성함이 특징이다.
Abstract:
PURPOSE: A cosmetic composition containing nutshell extract is provided to suppress proteinase-activated receptor-2(PAR-2) and to relieve itching. CONSTITUTION: A cosmetic composition for relieving or suppressing itching contains nutshell extract as an active ingredient. The composition prevents or relieves itching caused by inflammatory dermatitis, atopic dermatitis, miliaria, frostbite, contact dermatitis, seborrheic dermatitis, or pruritus. A cosmetic composition improving skin barrier function contains the nutshell extract as an active ingredient. The extract is prepared using water, low alcohol of C1-4, 1,3-butylene glycol, or mixture thereof.
Abstract:
본 발명은, CPT-1 프로모터와 루시퍼라제를 포함하는 재조합 플라스미드; 상기 플라스미드로 형질전환된 Huh7 세포주 (수탁번호: KCLRF-BP-00090); 상기 세포를 이용하는 것을 특징으로 하는, CPT-1 유전자의 발현을 특이적으로 전사 단계에서 조절하는 화학물질의 스크리닝 방법에 관한 것이며, 또한 본 발명은, 상기의 스크리닝 방법으로 검색된 제니스테인을 유효 성분으로 포함하는 CPT-1 발현 촉진제; 그리고 상기의 스크리닝 방법으로 검색된 제니스테인을 유효 성분으로 포함하는 지방산의 베타 산화 촉진제에 관한 것이다.
Abstract:
PURPOSE: A compound as a vinilloid receptor antagonist, an isomer thereof, and a pharmaceutical composition containing thereof are provided to secure the remarkably improved balance of the vinilloid receptor 1 activity and the PK properties. CONSTITUTION: A compound, an isomer thereof, and pharmaceutically acceptable salt thereof has the structure marked with chemical formula 1. In the chemical formula 1, R1 is hydrogen, methyl, or ethyl. R2 and R3 are independently, the hydrogen, halogen, cyano, the methyl, the ethyl, methoxy, trifluoromethyl, vinyl, or acetylenyl. R4 is either the trifluoromethyl or fluoro.
Abstract:
PURPOSE: A pharmaceutical composition containing 2-cyclopentene-1-one oxime derivative is provided to promote adipose lysis in adipocytes(3T3-L1) and to prevent and treat lipid metabolic diseases including obesity and diabetes. CONSTITUTION: A pharmaceutical composition for preventing and treating lipid metabolic diseases contains 2-cyclopenten-1-one oxime derivative compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. In chemical formula 1, R1 is linear or branched C1-C10 alkyl group or C3-C7 cycloalkyl group, or phenyl group with or without substituent. The phenyl group is denoted by chemical formula 2. The pharmaceutical composition is used for preventing and treating obesity, diabetes, or dyslipidemia.
Abstract:
PURPOSE: A novel compound which functions as a vanilloid receptor 1(VR1) antagonist is provided to prevent or treat disease related to hair growth, rhinitis, and pancreatitis. CONSTITUTION: A vanilloid receptor antagonist compound is denoted by chemical formula I. A pharmaceutical composition contains the compound, isomer, or pharmaceutically acceptable salt thereof. The composition is used for preventing or treating arthritis disease, neuropathy, HIV related neuropathy, nerve injury, neurodegeneration, cerebral apoplexy, urinary incontinence, cough, neuropathy/allergy/inflammation skin disease, atopic dermatitis, psoriasis, pruritus, the prurigo, acouesthesia, aliasing, bregma anaphylaxis, effluvium, or alopecia.
Abstract:
An extractor and an extracting method using a pottery are provided to create high pressure inside the extractor body in order to prevent extracts from contacting the extractor body of metal material. An extractor(200) comprises a hollow body(210) made of metal, a cover(220) closing the body, a heating part(230) heating the body from the outside, a pottery(240) placed inside the body, and a gas valve(250) which injects gas into the body or discharges gas from the body.
Abstract:
A compound as a vanilloid receptor antagonist is provided to obtain a pharmaceutical composition effective for preventing or treating pain, migraine, arthralgia, nerve injury, skin diseases, overactive bladder, irritable bowel syndrome, or the like. A compound as a vanilloid receptor antagonist, an isomer or a pharmaceutically acceptable salt thereof is represented by the following formula I. In formula I, X is NHCH2, CR11=CR12, NH, CHR11CHR12 or C=C, wherein each of R11 and R12 represents H, halogen, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl or phenyl; R1 is a C2-C5 alkenyl or C2-C5 alkynyl; R2 is H, halogen, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C2-C5 alkenyl, or C2-C5 alkynyl; R2 is H, halogen, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxyl, C1-C5 alkoxycarbonyl, C1-C5 alkylthio, phenyl or phenyl(C1-C3)alkyl, wherein is each phenyl group is non-substituted or substituted with at least one substituent; R3 is H, C1-C5 alkyl, C1-C5 alkoxy or halo(C1-C5)alkyl; each of R4, R5 R6, R7 and R8 independently represents H, carboxyl, C1-C5 alkyl, nitro, C2-C5 alkenyl, C1-C5 alkoxy, C2-C5 alkynyl, halo(C1-C5)alkyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, hydroxy, C2-C5 alkenyloxy, C1-C5 alkoxy(C1-C5)alkoxy, C1-C5 alkoxy(C1-C5)alkoxy(C1-C5)alkyl, C1-C3 alkylpiperazinyl, piperazinyl(C1-C5)alkoxy, piperidinyl(C1-C5)alkoxy, C1-C5 alkoxy (C1-C5)alkylamino, C1-C7 alkylamino, morpholinyl, morpholinyl(C1-C5)alkyloxy, tetrahydropyranyloxy, phenyl or halogen, wherein each phenyl group is non-substituted or substituted with at least one substituent; each of R9 and R10 independently represents H, -SO2R13, -SOR13, C1-C5 alkyl, C1-C5 alkoxy, halo (C1-C5)alkyl, C2-C5 alkenyl, C1-C5 alkoxycarbonyl, C1-C5 alkylthio, phenyl or phenyl (C1-C3)alkyl, wherein each phenyl group is non-substituted or substituted with at least one substituent, and R13 is H, amino, C1-C5 alkyl, C2-C5 alkenyl, C1-C5 alkoxy, halo(C1-C5)alkyl, trifluoromethyl, phenyl or phenyl(C1-C3)alkyl.